Features include: Confusion, Vivid hallucination, Excessive hunger (polyphagia), and Episodic hypersomnia.

No approved treatments are currently available for Kleine-Levin syndrome. An additional 1 compound holds orphan drug designation.

Orphan Drug Designations

While no drugs are FDA-approved specifically for Kleine-Levin syndrome, some of the following designated compounds may be used off-label in clinical practice. Treatment decisions should be made in consultation with a specialist familiar with this condition.

The following drugs have received orphan drug designation from the FDA for Kleine-Levin syndrome. Orphan designation reflects regulatory interest and does not indicate approval for treatment.

Estimated prevalence: 1-9 in 1,000,000 (Rare).

1 clinical trial registered, 1 recruiting. Interventions under study include other interventions. Research is primarily sponsored by academic and government institutions.